Analysts, who are highly bullish on the stock, have fretted for some time that Viking needed a partner to actually make the ...

Viking Therapeutics VKTX signed a broad multi-year manufacturing agreement with CordenPharma, a contract development and ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

CordenPharma, a CDMO focused on peptides and peptide-based therapeutics, announced a partnership with Viking Therapeutics.

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid ...

After Viking Therapeutics (VKTX) announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ...

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

Viking Therapeutics (VKTX) announced that it has signed a broad, multi-year manufacturing agreement with CordenPharma, a contract development ...